BC Innovations | Jan 31, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Gastric cancer; gastrointestinal cancer Cytotoxin-associated gene A (CagA) Studies in mice suggested that targeting the Helicobacter pylori protein CagA could be...
BC Week In Review | Jun 2, 2003
Company News

Chiron other research news

Researchers published in Science that the CagA protein appears to target H. pylori to host cell intercellular junctions and to disrupt junction mediated functions of epithelial cells, resulting in dysplastic alterations in epithelial cell morphology....
BC Week In Review | Dec 17, 2001
Company News

Hokkaido University other research news

Researchers published in Science evidence that CagA plays a role in induction of gastric epithelial cell proliferation following infection with H. pylori. They showed that phosphorylated CagA binds with the SH2-domain containing SHP-2 tyrosine phosphatase...
BioCentury | Dec 17, 2001
Tools & Techniques

Predicting H. pylori outcomes

To infect humans, H. pylori attaches to gastric epithelial cells and injects the CagA protein, which undergoes phosphorylation in the human cells. H. pylori that express CagA trigger an elongation and spreading of human cells...
BC Week In Review | Aug 17, 1998
Clinical News

Biomerica, OraVax regulatory update

ORVX received U.S. Patent No. 5,733,740 covering a method of detecting antibodies against the Cytotoxin Associated Gene A ( CagA ) protein expressed only by virulent strains of H. pylori. BMRA has an exclusive license to the...
BC Week In Review | Jul 20, 1998
Clinical News

OraVax regulatory update

ORVX received U.S. Patent No. 5,733,740 covering a method for detecting serum antibodies against the CagA protein of H. pylori, the bacterium associated with peptic ulcers and gastric cancer. OraVax Inc. (ORVX), Cambridge, Mass.  ...
BC Week In Review | Apr 20, 1998
Company News

Biomerica, OraVax deal

BMRA acquired an exclusive license to ORVX's Cytotoxin Associated Gene A ( CagA ) for diagnostic use. BMRA will develop physician office and clinical laboratory tests based on CagA to detect H. pylori. ORVX is eligible for...
BC Week In Review | Nov 18, 1996
Company News

OraVax, bioMerieux Vitek Inc. deal

bioMerieux received an exclusive worldwide license (except Japan) to develop in vitro diagnostics using CagA , an antigen component used in ORVX's H. pylori vaccines. ORVX will be eligible for royalties and retains rights to the...
BC Week In Review | Mar 20, 1995
Company News

Chiron Biocine SpA other research news

Chiron Biocine researchers published in Science the creation of a mouse model of infection with H. pylori, showing that clinical isolates of the pathogen were able to infect mice. Previous attempts using laboratory cultures have...
Items per page:
1 - 9 of 9